We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PROPOSED CHANGES TO CMS' REIMBURSEMENT FOR CARDIAC DEVICES 'PREMATURE,' SAYS HRS

PROPOSED CHANGES TO CMS' REIMBURSEMENT FOR CARDIAC DEVICES 'PREMATURE,' SAYS HRS

June 6, 2006

Changes to Medicare reimbursement rules proposed by the Centers for Medicare & Medicaid (CMS) will compromise treatments for a range of serious heart conditions, the Heart Rhythm Society (HRS) has announced.

It is "premature" to adopt the CMS proposal, the HRS said. "Patients and providers need a stable and predictable payment system, not one with such volatility and large swings in payments."

The HRS is primarily concerned about the impact the CMS' proposed new hospital inpatient payment system and FY 2007 rates would have on patient access to heart rhythm procedures to treat conditions such as atrial fibrillation, which the group says places nearly 2.2 million Americans at increased risk for heart disease and stroke.

These proposed reductions will "ultimately be translated into reduced patient access" to technologies such as implantable cardioverter defibrillators (ICDs) that prevent sudden cardiac arrest and cardiac ablations, "which are 90 percent effective in treating debilitating and life threatening cardiac arrhythmias," said Dwight Reynolds, HRS president. "Despite this convincing evidence" of the effectiveness of such devices, CMS' methodology would lead to severe payment decreases for ICDs, pacemakers and ablations, Reynolds said.

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

  • 07Mar

    FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Consortium Gets EU Funding to Develop Continuous Blood Pressure Monitoring Device

  • FDA Approves GSK’s Oral Drug for Chronic Kidney Disease-Related Anemia

  • Aspivix’s Carevix Cleared to Reduce Pain, Bleeding in Gynecological Procedures

  • FDA Warns That Energy Supplement Contains Active Cialis Ingredient

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing